Clinical development of IDH1 inhibitors for cancer therapy

医学 IDH1 内科学 不利影响 临床试验 肿瘤科 异柠檬酸脱氢酶 危险系数 安慰剂 置信区间 病理 基因 酶 化学 生物化学 替代医学 突变
作者
Mehrdad Zarei,Jonathan J. Hue,Omid Hajihassani,Hallie J. Graor,Erryk Katayama,Alexander W. Loftus,David Lawrence Bajor,Luke Daniel Rothermel,Ali Vaziri Gohar,Jordan Michael Winter
出处
期刊:Cancer Treatment Reviews [Elsevier BV]
卷期号:103: 102334-102334 被引量:39
标识
DOI:10.1016/j.ctrv.2021.102334
摘要

Isocitrate dehydrogenase 1 (IDH1) has been investigated as a promising therapeutic target in select cancers with a mutated version of the enzyme (mtIDH1). With only one phase III trial published to date and two indications approved for routine clinical use by the FDA, we reviewed the entire clinical trial portfolio to broadly understand mtIDH1 inhibitor activity in patients. We queried PubMed.gov and ClinicalTrials.gov to identify published and ongoing clinical trials related to IDH1 and cancer. Progression-free survival (PFS), overall survival (OS), 2-hydroxyglutarate levels, and adverse events were summarized. To date, ten clinical trials investigating mtIDH1 inhibitors among patients with diverse malignancies (cholangiocarcinoma, acute myeloid leukemia, chondrosarcoma, glioma) have been published. Almost every trial (80%) has investigated ivosidenib. In multiple phase I trials, ivosidenib treatment resulted in promising radiographic and biochemical responses with improved survival outcomes (relative to historic data) among patients with both solid and hematologic mtIDH1 malignancies. Among patients enrolled in a phase III trial with advanced cholangiocarcinoma, ivosidenib resulted in a PFS rate of 32% at 6 months, as compared to 0% with placebo. There was a 5.2 month increase in OS with ivosidenib relative to placebo, after considering crossover. The treatment-specific grade ≥3 adverse event rate of ivosidenib was 2%-26% among all patients, and was just 3.6% among 284 patients who had a solid tumor across four trials. Although <1% of malignancies harbor IDH1 mutations, small molecule mtIDH1 inhibitors, namely ivosidenib, appear to be biologically active and well tolerated in patients with solid and hematologic mtIDH1 malignancies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
爆米花的应助被予安采纳,获得30
刚刚
wanci的应助被迟安歌采纳,获得10
1秒前
younger发布了新的文献求助10
1秒前
2秒前
3秒前
5秒前
6秒前
毛毛发布了新的文献求助10
6秒前
7秒前
星辰大海的应助被喵喵呜喵喵采纳,获得30
7秒前
熊98完成签到,获得积分10
8秒前
香蕉觅云的应助被xixi采纳,获得10
8秒前
8秒前
THM666发布了新的文献求助10
9秒前
HZH完成签到 ,获得积分10
9秒前
9秒前
guts发布了新的文献求助10
11秒前
打打的应助被PPP采纳,获得10
11秒前
zyx发布了新的文献求助10
12秒前
younger完成签到,获得积分10
12秒前
12秒前
12秒前
HD完成签到,获得积分10
13秒前
李健的应助被爱而不得采纳,获得10
13秒前
整箱发布了新的文献求助10
14秒前
夙夙完成签到,获得积分10
15秒前
科目三的应助被嘿嘿采纳,获得10
15秒前
15秒前
16秒前
16秒前
小刘的应助被车水采纳,获得50
16秒前
夙夙发布了新的文献求助10
18秒前
Grin完成签到,获得积分10
18秒前
小余完成签到,获得积分10
18秒前
小貉发布了新的文献求助10
19秒前
顺利发布了新的文献求助10
20秒前
洁净山柏发布了新的文献求助10
22秒前
充电宝的应助被QLK采纳,获得10
22秒前
24秒前
万能图书馆的应助被顺利采纳,获得10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188563
求助须知:如何正确求助?哪些是违规求助? 9576328
关于积分的说明 21846521
捐赠科研通 7786563
什么是DOI,文献DOI怎么找? 3435354
关于科研通互助平台的介绍 2559627
邀请新用户注册赠送积分活动 2482336